To confirm the interaction between CD2BP2‐DT and YBX1 in breast cancer cells, we conducted biotin‐labeled RNA pull‐down and RNA immunoprecipitation (RIP) assays (Figure 3E,F). Here, CD2BP2 is linked to breast carcinoma.